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Background: Rifampicin remains one of the first-line drugs used in tuberculosis therapy. This drug´s potential to
induce the hepatic cytochrome P450 oxidative enzyme system increases the risk of drug-drug interactions. Thus,
although the presence of comorbidities typically necessitates the use of multiple drugs, the co-administration of
rifampicin and warfarin may lead to adverse drug events. We report a bleeding episode after termination of the
co-administration of rifampicin and warfarin and detail the challenges related to international normalized ratio
(INR) monitoring.
Case presentation: A 59-year-old Brazilian woman chronically treated with warfarin for atrial fibrillation
(therapeutic INR range: 2.0-3.0) was referred to a multidisciplinary anticoagulation clinic at a university hospital.
She showed anticoagulation resistance at the beginning of rifampicin therapy, as demonstrated by repeated
subtherapeutic INR values. Three months of sequential increases in the warfarin dosage were necessary to reach a
therapeutic INR, and frequent visits to the anticoagulation clinic were needed to educate the patient about her
pharmacotherapy and to perform the warfarin dosage adjustments. The warfarin dosage also had to be doubled
at the beginning of rifampicin therapy. However, four weeks after rifampicin discontinuation, an excessively high
INR was observed (7.22), with three-day macroscopic hematuria and the need for an immediate reduction in the
warfarin dosage. A therapeutic and stable INR was eventually attained at 50% of the warfarin dosage used by the
patient during tuberculosis therapy.
Conclusions: The present case exemplifies the influence of rifampicin therapy on warfarin dosage requirements
and the increased risk of bleeding after rifampicin discontinuation. Additionally, this case highlights the need for
warfarin weekly monitoring after stopping rifampicin until the maintenance dose of warfarin has decreased to the
amount administered before rifampicin use. In particular, patients with cardiovascular diseases and active
tuberculosis represent a group with a substantial risk of drug-drug interactions. Learning how to predict and
monitor drug-drug interactions may help reduce the incidence of clinically significant adverse drug events.
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Rifampicin remains one of the first-line drugs used to
treat tuberculosis (TB) [1,2]. This drug´s use is increas-
ingly common due to the frequency of coinfection with
TB and human immunodeficiency virus (HIV) [3,4] and
the spread of TB within vulnerable populations [5,6].
Comorbidities and polypharmacy, which are particu-
larly prevalent in older adults, are associated with
higher risk of drug-drug interactions [7]. Rifampicin is
also a potent inducer of the hepatic cytochrome P450
(CYP) oxidative enzyme system and the P-glycoprotein
transport system [8]. The acceleration of drug clear-
ance related to CYP induction by rifampicin may com-
promise the therapeutic efficacy of several drugs. There
are several well-documented examples of clinically
significant drug-drug interactions during rifampicin
therapy, including interactions between warfarin and
rifampicin [8,9].
Warfarin is a coumarin derivative that is widely used
to prevent and treat thromboembolic disorders. Racemic
warfarin accumulates in the liver, in which both the R
and the S enantiomers are metabolically transformed by
different pathways [10]. The S enantiomer is approxi-
mately 90% oxidatively metabolized, primarily by the
CYP2C9 enzyme of the CYP system and, to a lesser ex-
tent, by CYP3A4. The less potent R enantiomer is ap-
proximately 60% oxidatively metabolized, primarily by
the two CYP enzymes CYP1A2 and CYP3A4 and, to a
lesser extent, by CYP2C19 [11].
Rifampicin is known to reduce the effect of warfarin
on prothrombin activity. This drug-drug interaction
has been described in individual case reports [12-18]
and pharmacokinetic studies [19-21]. The effect of the
rifampicin-warfarin interaction on the anticoagulant
response can be tested using the international nor-
malized ratio (INR), which is the current standard for
monitoring warfarin responses. Patients with sub- and
supratherapeutic INR values are at a higher risk of clin-
ical complications [11]. However, there are no pub-
lished long-term follow-up studies focused on bleeding
events and INR values after termination of the co-
administration of rifampicin and warfarin.
In this report, we describe a 35-month follow-up of
a patient chronically treated with warfarin for atrial
fibrillation (AF) and undergoing concomitant 6-month
TB therapy. Warfarin resistance was observed at the
beginning of the TB treatment, and a continuous dos-
age increase was required to achieve and maintain
INR control. Following rifampicin discontinuation, the
patient was diagnosed with macroscopic hematuria,
and the warfarin dosage was gradually decreased to
stabilize the INR within the therapeutic range. Here,
we also review studies focusing on the rifampicin-
warfarin interaction.Case presentation
A 59-year-old, non-white woman was diagnosed with
AF in May 2009, when warfarin therapy was initiated
with a therapeutic INR range of 2.0-3.0. She was re-
ferred to the anticoagulation clinic of a university hos-
pital in March 2010. Her typical warfarin dosage was
nearly 52.5 mg/week. The patient’s medical history in-
cluded systemic arterial hypertension, pulmonary arter-
ial hypertension, rheumatic cardiopathy, asthma and
chronic emphysema. She was also subjected to a biological
mitral valve replacement in 2006. The patient denied any
alcohol consumption and showed no evidence of hepatic
or renal dysfunction. Her drug list included ferrous sulfate,
hydrochlorothiazide and enalapril.
By the time the patient was sent for outpatient
anticoagulation control, she had been diagnosed with
pleural TB and had begun treatment with isoniazid
(400 mg/day), rifampicin (600 mg/day) and pyrazinamide
(2 g/day). The pyrazinamide was discontinued after
two months. Subtherapeutic INR values were obtained
for several weeks after initiating TB therapy. Routine
reevaluations were necessary for INR monitoring and
warfarin dosage adjustments. Thus, the warfarin dosage
was gradually increased from 45 mg/week to 80 mg/week.
Three months were necessary to reach a stable INR, which
was maintained for an additional three months.
On October 15th, 2010, the patient´s rifampicin and iso-
niazid use was discontinued by an infectious disease spe-
cialist. One week later, a therapeutic INR of 2.02 was
obtained. On November 11th, 2010, the patient noticed
significant macroscopic hematuria that lasted for three
days and a supratherapeutic INR (7.22) was measured on
the same day. The warfarin doses were interrupted for two
days, and the weekly dose was reduced from 77.5 mg to
52.5 mg (33%), according to the hospital protocol. Vitamin
K or fresh frozen plasma was not administered due to the
absence of hemodynamic instability or another reason jus-
tifying immediate INR reduction. Five days after the dose
reduction, the patient´s INR was 2.29. The patient had no
history of bleedings, and there were no reported dosing er-
rors or changes in drug therapy, vitamin K intake or med-
ical status. A urinalysis performed five days after the first
bleeding episode showed no significant presence of eryth-
rocytes. Afterward, INR control was reached at a weekly
warfarin dose of 37.5 mg. Sequential INR values and re-
lated warfarin weekly doses for the 35-month follow-up
are presented in Figure 1.
Discussion
In this case report, a patient chronically treated with
warfarin showed anticoagulation resistance at the begin-
ning of rifampicin therapy, as demonstrated by repeated
subtherapeutic INR values. During this phase, there was an
augmented risk of cardioembolic events. Three months of
Figure 1 Weekly warfarin dosage, INR values, and concurrent rifampin therapy over time. The x-axis represents time in relation to the
dates of the patient’s anticoagulation clinic appointments. The left y-axis represents the prescribed warfarin dosage in milligrams/week, which is
shown by the vertical bars. The right y-axis represents the INR values, which are depicted by the black points (therapeutic range: 2.0-3.0).
The time period of the concurrent rifampin therapy is shown as a horizontal dark bar.
Table 1 Summary of recent studies reporting drug-drug interactions involving rifampicin and warfarin in humans















1 Male 58 Yes Yes No A 233% increase in the warfarin dose
over four months could not attain a
therapeutic INR* during the use of
rifampicin. A therapeutic INR* was
obtained after a 70% reduction in the






1 Male 79 Yes Yes No Increases of 500-600% in the warfarin
dose were insufficient to maintain an
INR* in the therapeutic range. After
rifampicin was discontinued, the
warfarin dose was gradually reduced






1 Male 71 Yes Yes No The warfarin dose was sequentially
increased by up to 500%, from a
starting point of 35–40 mg/week to
an endpoint of 175 mg/week over
two months, with no achievement
of a therapeutic INR*. After rifampicin
discontinuation, the warfarin dose
was gradually reduced to the initial
regimen over three to four months
to attain a therapeutic INR*.
* INR international normalized ratio.
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to reach a therapeutic INR. A hyperanticoagulation state
occurred after discontinuation of rifampicin, resulting in
macroscopic hematuria and the need for an immediate re-
duction in the warfarin dosage. The patient´s INR was still
within the therapeutic range one week after withdrawing
rifampicin. However, a supratherapeutic INR value and
bleeding were observed four weeks after the interruption
of rifampicin therapy, suggesting a delayed offset of the
rifampicin-warfarin interaction. The evaluation of the
present case was based on the criteria for adverse event re-
ports proposed by Kelly [22]. The Naranjo algorithm [23]
and the Drug Interaction Probability Scale (DIPS) [24]
were also employed to evaluate the causality of the adverse
event. The effect of each medication on the warfarin anti-
coagulant response was considered. Rifampicin showed a
score of 8 (probable) for both methods, which was the
highest score obtained for the medications in use.
The proposed mechanism for the rifampicin-warfarin
interaction involves the induction of the isoenzymes
CYP2C9, CYP3A4, CYP1A2 and CYP2C19 [25,26], ac-
celerating the clearance of both the R and the S enantio-
mers of warfarin. Enzyme induction typically exhibits a
slow onset and long-term recovery time. In particular,
CYP induction depends on the synthesis of new drug-
metabolizing enzymes, with the initial effects detectable
within the first two days of concurrent therapy. How-
ever, it generally takes at least one week to observe the
effects of maximal induction. The onset of CYP stimula-
tion is also dependent on the half-life of the inducer. As
rifampicin exhibits a relatively short half-life, steady-
state serum concentrations are obtained faster when ri-
fampicin is compared with other inducing drugs with
longer half-lives [26,27]. The dissipation of CYP induc-
tion after the discontinuation of rifampicin occurs grad-
ually, depending on the drug´s elimination and the
gradual decay of the enhanced enzymatic activity in the
liver [8,26]. The concurrent use of isoniazid may cause
an opposite effect on the liver by inhibiting CYP3A4
[28-30], leading to the accumulation of the less potent R
enantiomer. As an additional mechanism, an acquired
inhibition of fibrin stabilization has been associated with
isoniazid therapy [31]. In the present case, the stimula-
tory effect of rifampicin on the liver seemed to be clinic-
ally predominant over the effect of the concomitant use
of isoniazid on the coagulation state, which is consistent
with previous findings [12,14,15].
The prediction of a patient’s response to warfarin and
of the precise magnitude of the dosage adjustments re-
quired when rifampicin is initiated or discontinued is
challenging. In the case presented here, it was necessary
to double the warfarin dose at the beginning of rifampi-
cin therapy and to reduce the warfarin dose by approxi-
mately 50% after discontinuing rifampicin to attain atherapeutic INR. Other recent case reports have demon-
strated an increased sensitivity to warfarin after stopping
rifampicin therapy and the need for more than four weeks
to achieve a therapeutic INR, until the drug-drug inter-
action dissipated [16-18]. However, supratherapeutic INR
values were not associated with bleeding in these studies
(Table 1).
The potential of rifampicin to induce warfarin metabol-
ism has been well known for decades, although only a lim-
ited number of case reports have been published. In the
current report, long-term INR monitoring helped demon-
strate the effect that the concomitant use of rifampicin
may have on the warfarin anticoagulant response and on
the risk of adverse events, such as bleeding. Our report
serves to forewarn health professionals that a patient
should be monitored weekly after stopping rifampicin,
until the maintenance dose of warfarin has decreased to
the dose administered before the use of rifampicin. Al-
though our findings cannot be generalized, this case report
illustrates the increased risk of drug-drug interactions in
patients with comorbidities and complex dosing regimens.
Close monitoring and patient education may help improve
the quality of care delivered to these patients.
Conclusions
This case demonstrated the influence of rifampicin therapy
on warfarin dose requirements and the increased risk of
bleeding. The INR should be monitored weekly until a new
stable dose is achieved after rifampicin discontinuation to
prevent clinical complications related to unstable INR
values. In particular, patients with cardiovascular diseases
and active TB represent a group with a substantial risk of
drug-drug interactions. Learning how to predict and moni-
tor drug-drug interactions may help reduce the incidence
of clinically significant adverse drug events.
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